Background: Parkinson’s disease (PD) is depicted as the most prevailed neurodegenerative
disease being secondary to the Alzheimer’s disease. PD is featured by severe dropping of dopamine related
neurons present in substantia nigra as well as cytoplasmic inclusions. A number of therapeutic
agents are available to treat initial as well as later complications of PD. However, transport of neurotherapeutics
into the brain has been a consistent challenge for researchers, because of the existence of
blood-brain barrier (BBB). In some last decades, nasal delivery pathway has gained extensive deliberations.
Intranasal administration as a way to target neurotherapeutics to the central nervous system bypassing
blood brain barrier, exhibit several advantages for treating neurodegenerative disorders. This
route for transport of neurotherapeutics offers the merits of convenience of administration, avoidance of
pre-systemic hepatic metabolism, and non- invasiveness.
Methods: Novel nano-sized formulations researched for intranasal transport of various actives have
been reviewed using search engine “Scopus”. Feasibility of various nano-carriers systems such as nanoemulsions,
lipid nanoparticles and polymeric micelles has been elaborated. The write up traces the preclinical
and pharmacokinetic aspects of the nano-formulations.
Results: Nano-formulations are the rising formulations in PD treatment as they offer targeted drug delivery,
enhanced therapeutic efficacy and decreased systemic side effects of neurotherapeutics. These
formulations provide effective intranasal transport by encapsulating drug, protecting it from biological/
chemical degradation and extracellular transport through P-glycoprotein (P-gp) efflux thus, and enhancing
CNS availability for drugs.
Conclusion: Thus, it can be put into conclusion that nano-neurotechnology; particularly application of
nanotechnology has yielded potential outcomes in upcoming years.